ロード中...
The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-β1
Kidney fibrosis and fibrogenesis significantly exacerbate chronic kidney disease (CKD) progression and are essential therapeutic targets. Bortezomib (BZM) is a proteasome inhibitor used for the treatment of multiple myeloma (MM). Several studies have demonstrated that BZM attenuates renal impairment...
保存先:
| 出版年: | Sci Rep |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Nature Publishing Group UK
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5638992/ https://ncbi.nlm.nih.gov/pubmed/29026167 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-017-13486-x |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|